Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples

Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertini...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiura, Katsuyuki, Yoh, Kiyotaka, Katakami, Nobuyuki, Nogami, Naoyuki, Kasahara, Kazuo, Takahashi, Toshiaki, Okamoto, Isamu, Cantarini, Mireille, Hodge, Rachel, Uchida, Hirohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891183/
https://www.ncbi.nlm.nih.gov/pubmed/29363250
http://dx.doi.org/10.1111/cas.13511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891183/
https://www.ncbi.nlm.nih.gov/pubmed/29363250
http://dx.doi.org/10.1111/cas.13511

Ejemplares similares